JSC Kalceks launches Hydromorphone Kalceks 2, 10, 20 and 50 mg/ml solution for injections/infusions
JSC Kalceks starts production and commercialization of Hydromorphone Kalceks 2, 10, 20 and 50 mg/ml solution for injections/infusions. Product has been registered via decentralized registration procedure involving 10 European Union countries. First sales are expected in Germany and Netherlands following by other EU countries.
Hydromorphone is a semi-synthetic opioid for the treatment of severe pain and acts more potent than morphine (5-8 times as potent in this capacity). Hydromorphone Kalceks is indicated in adults and adolescents over 12 years of age.
Hydromorphone has superior speed of onset and less troublesome side effect and less dependence liability profile than Morphine.
Hydromorphone is extensively metabolized in the liver to non-active metabolites, therefore, it is safe to use in patients with renal failure.
Hydromorphone Kalceks 2, 10, 20 and 50 mg/ml solution for injections/infusions is a third new product that Kalceks launches within this year.